BACE1 structure and function in health and Alzheimer's disease

Current Alzheimer Research

Volumn 5, Issue 2, 2008, Pages 100-120

  Cole, Sarah L ^a   Vassar, Roger ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

amyloid; secretase; Alzheimer's; APP; BACE1; Function; Risk factors; Structure

Indexed keywords

AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BETA SECRETASE; GAMMA SECRETASE;

ALZHEIMER DISEASE; BEHAVIOR CHANGE; BRAIN LEVEL; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; ENZYME SUBSTRATE; HEALTH; HUMAN; HYPERCHOLESTEROLEMIA; HYPOXIA; INTRACELLULAR TRANSPORT; KNOCKOUT MOUSE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SENILE PLAQUE; SEQUENCE HOMOLOGY; TRAUMATIC BRAIN INJURY; VALIDATION STUDY; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; HEALTH; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 42149130900     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783954758     Document Type: Review

References (252)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923 (1993).
2. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, and Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11: 601-607 (1990).
3. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-1145 (1996).
4. Soneira CF and Scott TM. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat 9: 118-127 (1996).
5. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137: 149-155 (2002).
6. Skoog I and Gustafson D. Hypertension and related factors in the etiology of Alzheimer's disease. Ann N Y Acad Sci 977: 29-36 (2002).
7. Hutton M, Perez-Tur J and Hardy J. Genetics of Alzheimer's disease. Essays Biochem 33: 117-131 (1998).
8. Younkin SG. The role of Abeta 42 in Alzheimer's disease. J Physiol (Paris) 92: 289-292 (1998).
9. Sisodia SS, Kim SH and Thinakaran G. Function and dysfunction of the presenilins. Am J Hum Genet 65: 7-12 (1999).
10. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38: 24-26 (2006).
11. Wolfe MS, Angeles JDL, Miller DD, Xia W and Selkoe DJ. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry 38: 11223-11230 (1999).
12. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT and Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398: 513-517 (1999).
13. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature 407: 48-54 (2000).
14. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J., et al. Aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 3: 85-97 (2002).
15. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 422: 438-441 (2003).
16. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767 (1998).
17. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927 (1999).
18. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741 (1999).
19. Skovronsky DM, Moore DB, Milla ME, Doms RW, and Lee V.M. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem 275: 2568-2575 (2000).
20. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
21. Tanzi RE, Gusella JF, Watkins PC, Bruns GAB, St. George-Hyslop PH, Van Keuren M, et al. Amyloid β-protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235: 880-884 (1987).
22. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325 (1992).
23. Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomqist C, Davis DL, et al. Secretion of β-amyloid precursor protein cleaved at the amino-terminus of the β-amyloid peptide. Nature 361: 260-263 (1993).
24. Zhao J, Paganini L, Mucke L, Gordon M, Refolo L, Carman M, et al. β-Secretase processing of the β-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. J Biol Chem 271: 31407-31411 (1996).
25. Citron M, Teplow DB and Selkoe DJ. Generation of amyloid β-protein from its precursor is sequence specific. Neuron 14: 661-670 (1995).
26. Haass C, Hung AY, Schlossmacher MG, Teplow DB and Selkoe DJ. β-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268: 3021-3024 (1993).
27. Haass C, Capell A, Citron M, Teplow DB and Selkoe DJ. The vacuolar H+ ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type β-amyloid precursor protein. J Biol Chem 270: 6186-6192 (1995).
28. Knops J, Suomensaari S, Lee M, McConlogue L, Seubert P and Sinha S. Cell-type and amyloid precursor protein-type specific inhibition of Aβ release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. J Biol Chem 270: 2419-2422 (1995).
29. Koo EH and Squazzo S. Evidence that production and release of amyloid β-protein involves the endocytic pathway. J Biol Chem 269: 17386-17389 (1994).
30. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway. Nature Med 1: 1291-1296 (1995).
31. Turner RT, 3rd, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, et al. Subsite specificity of memapsin 2 (betasecretase): implications for inhibitor design. Biochemistry 40: 10001-10006 (2001).
32. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268: 3072-3083 (1993).
33. Citron M, Diehl TS, Capell A, Haass C, Teplow DB, and Selkoe DJ. Inhibition of amyloid β-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron 17: 171-179 (1996).
34. Gouras GK, Xu H, Jovanovic JN, Buxbaum JD, Wang R, Greengard P, et al. Generation and regulation of β-amyloid peptide variants by neurons. J Neurochem 71: 1920-1925 (1998).
35. Creemers JW, Ines Dominguez D, Plets E, Serneels L, Taylor NA, Multhaup G, et al. Processing of β-secretase by furin and other members of the proprotein convertase family. J Biol Chem 276: 4211-4217 (2001).
36. Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, et al. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J Biol Chem 278: 5531-5538 (2003).
37. Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski J, et al. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol 168: 291-302 (2005).
38. Lazarov O, Lee M, Peterson DA, and Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22: 9785-9793 (2002).
39. Sheng JG, Price DL, and Koliatsos VE. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci 22: 9794-9799 (2002).
40. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as β-Secretase. Mol Cell Neurosci 14: 419-427 (1999).
41. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402: 537-540 (1999).
42. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 402: 533-537 (1999).
43. Lin X, Koelsch G, Wu S, Downs D, Dashti A, and Tang J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc. Natl. Acad. Sci. USA 97: 1456-1460 (2000).
44. Bennett BD, Denis P, Haniu M, Teplow DB, Kahn S, Louis J-C, et al. A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's β-secretase. J Biol Chem 275: 37712-37717 (2000).
45. Benjannet S, Elagoz A, Wickham L, Mamarbachi M, Munzer JS, Basak A, et al. Post-translational processing of beta-secretase (beta-amyloid- converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem 276: 10879-10887 (2001).
46. Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, et al. Characterization of Alzheimer's β-secretase protein BACE. J Biol Chem 275: 21099-21106 (2000).
47. Marcinkiewicz M and Seidah NG. Coordinated expression of β-amyloid precursor protein and the putative β-secretase BACE and α-secretase ADAM10 in mouse and human brain. J Neurochem 75: 2133-2143 (2000).
48. Bodendorf U, Fischer F, Bodian D, Multhaup G and Paganetti P. A splice variant of β-secretase deficient in the amyloidogenic processing of the amyloid precursor protein. J Biol Chem 276: 12019-12023 (2001).
49. Ehehalt R, Michel B, De Pietri Tonelli D, Zacchetti D, Simons K and Keller P. Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. Biochem Biophys Res Commun 293: 30-37 (2002).
50. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533-537 (1999).
51. Saunders AJ, Kim TW, Tanzi RE, Fan W, Bennett BD, Babu-Khan S, et al. BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science 286: 1255a (1999).
52. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 19: 739-749 (2005).
53. Hussain I, Christie G, Schneider K, Moore S and Dingwall C. Prodomain processing of Asp1 (BACE2) is autocatalytic. J Biol Chem 276: 23322-23328 (2001).
54. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275: 20647-20651 (2000).
55. Farzan M, Schnitzler CE, Vasilieva N, Leung D, and Choe H. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc Natl Acad Sci USA 97: 9712-9717 (2000).
56. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol Cell Neurosci 16: 609-619 (2000).
57. Yan R, Munzner JB, Shuck ME and Bienkowski MJ. BACE2 functions as an alternative α-secretase in cells. J Biol Chem 276: 34019-34027 (2001).
58. Basi G, Frigon N, Barbour R, Doan T, Gordon G, McConlogue L, et al. Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. J Biol Chem 278: 31512-31520 (2003).
59. Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, et al. BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 4: 81-88 (2003).
60. Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, et al. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem 81: 1011-1020 (2002).
61. Sun X, He G and Song W. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J 20: 1369-1376 (2006).
62. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nature Neurosci 4: 233-234 (2001).
63. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci. 4: 231-232 (2001).
64. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317-1324 (2001).
65. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-103 (1996).
66. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693-11709 (2005).
67. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease. Neuron 41: 27-33 (2004).
68. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077-4081 (1996).
69. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100: 10417-10422 (2003).
70. Hsiao Ashe K. Learning and Memory in Transgenic Mice Modeling Alzheimer's Disease. Learn Mem 8: 301-308 (2001).
71. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26: 10129-10140 (2006).
72. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, et al. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 23: 251-260 (2006).
73. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M and Berry R. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26: 134-145 (2007).
74. Ohno M. Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. Rev Neurosci 17: 429-454 (2006).
75. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG and Gage FH. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343-1349 (2005).
76. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280: 30797-30806 (2005).
77. Lange-Dohna C, Zeitschel U, Gaunitz F, Perez-Polo JR, Bigl V and Rossner S. Cloning and expression of the rat BACE1 promoter. J Neurosci Res 73: 73-80 (2003).
78. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S and Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 24: 865-874 (2004).
79. Ge YW, Maloney B, Sambamurti K, and Lahiri DK. Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB J 18: 1037-1039 (2004).
80. Sambamurti K, Kinsey R, Maloney B, Ge YW and Lahiri DK. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 18: 1034-1036 (2004).
81. Lahiri DK, Ge YW, Rogers JT, Sambamurti K, Greig NH and Maloney B. Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors. Curr Alzheimer Res 3: 475-483 (2006).
82. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E and Borghgraef P. Nonsteroidal anti-inflammatory drugs repress betasecretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103: 443-448 (2006).
83. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421 (2000).
84. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG and Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 85: 1194-1204 (2007).
85. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P and Grubeck-Loebenstein B. Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol Dis 7: 682-689 (2000).
86. Hong HS, Hwang EM, Sim HJ, Cho HJ, Boo JH, Oh SS, et al. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 307: 922-927 (2003).
87. Cho HJ, Kim SK, Jin SM, Hwang EM, Kim YS, Huh K, et al. IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia 55:253-262 (2007).
88. Rossner S, Apelt J, Schliebs R, Perez-Polo JR and Bigl V. Neuronal and glial β-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res 64: 437-446 (2001).
89. Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H and Stahl T. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 41: 169-179 (2003).
90. Leuba G, Wernli G, Vernay A, Kraftsik R, Mohajeri MH and Saini KD. Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. Dement Geriatr Cogn Disord 19:171-183 (2005).
91. Rossner S, Lange-Dohna C, Zeitschel U and Perez-Polo JR. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem 92: 226-234 (2005).
92. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, et al. Betasite amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 27: 3639-3649 (2007).
93. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128: 1442-1453 (2005).
94. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflamm 2: 22 (2005).
95. Bigl M, Apelt J, Luschekina EA, Lange-Dohna C, Rossner S and Schliebs R. Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. Neurosci Lett 292: 107-110 (2000).
96. Irizarry MC, Locascio JJ and Hyman BT. beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol 158: 173-177 (2001).
97. Lammich S, Schobel S, Zimmer AK, Lichtenthaler SF and Haass C. Expression of the Alzheimer protease BACE1 is suppressed via its 5′-untranslated region. EMBO Rep 5: 620-625 (2004).
98. Rogers GW Jr, Edelman GM and Mauro VP. Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci USA 101: 2794-2799 (2004).
99. De Pietri Tonelli D, Mihailovich M, Di Cesare A, Codazzi F, Grohovaz F and Zacchetti D. Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res 32: 1808-1817 (2004).
100. Capell A, Steiner H, Willem M, Kaiser H, Meyer C, Walter J, et al. Maturation and pro-peptide cleavage of beta-secretase. J Biol Chem 275: 30849-30854 (2000).
101. Huse JT, Pijak DS, Leslie GJ, Lee VM and Doms RW. Maturation and endosomal targeting of β-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease β-secretase. J Biol Chem 275: 33729-33737 (2000).
102. Charlwood J, Dingwall C, Matico R, Hussain I, Johanson K, Moore S, et al. Characterization of the glycosylation profiles of Alzheimer's β-secretase protein Asp-2 expressed in a variety of cell lines. J Biol Chem 276: 16739-16748 (2001).
103. Ghosh AK, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, et al. Design of Potent Inhibitors for Human Brain Memapsin 2 (beta-Secretase). Am J Chem Soc 122: 3522-3523 (2000).
104. Hussain I, Hawkins J, Shikotra A, Riddell DR, Faller A and Dingwall C. Characterization of the ectodomain shedding of the betasite amyloid precursor protein-cleaving enzyme 1 (BACE1). J Biol Chem 278: 36264-36268 (2003).
105. Murayama KS, Kametani F and Araki W. Extracellular release of BACE1 holoproteins from human neuronal cells. Biochem Biophys Res Commun 338: 800-807 (2005).
106. Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 52: 1168-1174 (2006).
107. Ermolieff J, Loy JA, Koelsch G and Tang J. Proteolytic activation of recombinant pro-memapsin 2 (Pro-beta-secretase) studied with new fluorogenic substrates. Biochemistry 39: 16263 (2000).
108. Shi XP, Chen E, Yin KC, Na S, Garsky VM, Lai MT, et al. The pro domain of β-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J Biol Chem 276: 10366-10373 (2001).
109. Riddell DR, Christie G, Hussain I, and Dingwall C. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, non-caveolar lipid rafts. Curr Biol 11: 1288-1293 (2001).
110. Ehehalt R, Keller P, Haass C, Thiele C, and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160: 113-123 (2003).
111. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280: 36815-36823 (2005).
112. Cordy J, Hussain I, Dingwall C, Hooper NM and Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 100: 11735-11740 (2003).
113. Schmechel A, Strauss M, Schlicksupp A, Pipkorn R, Haass C, Bayer TA, et al. Human BACE forms dimers and colocalizes with APP. J Biol Chem 279: 39710-39717 (2004).
114. Westmeyer GG, Willem M, Lichtenthaler SF, Lurman G, Multhaup G, Assfalg-Machleidt I, et al. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem 279: 53205-53212 (2004).
115. Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W and Turnbull JE. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol 163: 97-107 (2003).
116. He W, Lu Y, Qahwash I, Hu XY, Chang A and Yan R. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med 10: 959-965 (2004).
117. Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, et al. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase betasite APP-cleaving enzyme. J Neurosci 26: 418-428 (2006).
118. Xie J and Guo Q. PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J Biol Chem 280: 13824-13832 (2005).
119. Angeletti B, Waldron KJ, Freeman KB, Bawagan H, Hussain I, Miller CC, et al. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem 280: 17930-17937 (2005).
120. Wickham L, Benjannet S, Marcinkiewicz E, Chretien M and Seidah NG. Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin. J Neurochem 92: 93-102 (2005).
121. Kuzuya A, Uemura K, Kitagawa N, Aoyagi N, Kihara T, Ninomiya H, et al. Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Neurosci Res 85: 153-165 (2007).
122. Naruse S, Thinakaran G, Luo JJ, Kusiak JW, Tomita T, Iwatsubo T, et al. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 21: 1213-1221 (1998).
123. Zhang M, Haapasalo A, Kim DY, Ingano LA, Pettingell WH and Kovacs DM. Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment. FASEB J 20: 1176-1178 (2006).
124. Huse JT and Doms RW. Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol Neurobiol 22: 81-98 (2000).
125. Walter J, Fluhrer R, Hartung B, Willem M, Kaether C, Capell A, et al. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem 276: 14634-14641 (2001).
126. Pastorino L, Ikin AF, Nairn AC, Pursnani A and Buxbaum JD. The carboxyl-terminus of BACE contains a sorting signal that regulates BACE trafficking but not the formation of total A(beta). Mol Cell Neurosci 19: 175-185 (2002).
127. He X, Chang WP, Koelsch G and Tang J. Memapsin 2 (betasecretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2. FEBS Lett 524: 183-187 (2002).
128. Shiba T, Kametaka S, Kawasaki M, Shibata M, Waguri S, Uchiyama Y, et al. Insights into the phosphoregulation of beta-secretase sorting signal by the VHS domain of GGA1. Traffic 5: 437-448 (2004).
129. von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A, et al. Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci 117: 5437-5445 (2004).
130. He X, Li F, Chang WP and Tang J. GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J Biol Chem 280: 11696-11703 (2005).
131. Wahle T, Prager K, Raffler N, Haass C, Famulok M and Walter J. GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol Cell Neurosci 29: 453-461 (2005).
132. Puertollano R and Bonifacino JS. Interactions of GGA3 with the ubiquitin sorting machinery. Nat Cell Biol 6: 244-251 (2004).
133. Koh YH, von Arnim CA, Hyman BT, Tanzi RE and Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem 280: 32499-32504 (2005).
134. von Arnim CA, Spoelgen R, Peltan ID, Deng M, Courchesne S, Koker M, et al. GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. J Neurosci 26: 9913-9922 (2006).
135. Wahle T, Thal DR, Sastre M, Rentmeister A, Bogdanovic N, Famulok M, et al. GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci 26: 12838-12846 (2006).
136. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54: 721-737 (2007).
137. Capell A, Meyn L, Fluhrer R, Teplow DB, Walter J and Haass C. Apical sorting of beta-secretase limits amyloid beta-peptide production. J Biol Chem 277: 5637-5643 (2002).
138. Sheng JG, Price DL and Koliatsos VE. The beta-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain. Exp Neurol 184: 1053-1057 (2003).
139. Puglielli L, Ellis BC, Saunders AJ and Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278: 19777-19783 (2003).
140. Huse JT, Byant D, Yang Y, Pijak DS, D'Souza I, Lah JJ, et al. Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation. J Biol Chem 278: 17141-17149 (2003).
141. Qing H, Zhou W, Christensen MA, Sun X, Tong Y and Song W. Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J 18: 1571-1573 (2004).
142. Sauder JM, Arthur JW and Dunbrack RL Jr. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein β-secretase. J Mol Biol 300: 241-248 (2000).
143. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 290: 150-153 (2000).
144. Hong L, Turner RT 3rd, Koelsch G, Shin D, Ghosh AK and Tang J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry 41: 10963-10967 (2002).
145. Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 31: 713-726 (2001).
146. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D and Iwatsubo T. APP processing and synaptic function. Neuron 37: 925-937 (2003).
147. Plant LD, Webster NJ, Boyle JP, Ramsden M, Freir DB, Peers C, et al. Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ current. Neurobiol Aging 27: 1673-1683 (2006).
148. Li Q and Sudhof TC. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279: 10542-10550 (2004).
149. Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, et al. BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25: 642-649 (2004).
150. Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ and D'Adamio L. Processing of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription. J Biol Chem 277: 44195-44201 (2002).
151. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 46: 541-554 (2005).
152. Murayama KS, Kametani F, Saito S, Kume H, Akiyama H and Araki W. Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein. Eur J Neurosci 24: 1237-1244 (2006).
153. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9: 1520-1525 (2006).
154. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al. Control of peripheral nerve myelination by the betasecretase BACE1. Science 314: 664-666 (2006).
155. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA and Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643-648 (2001).
156. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, et al. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 280: 23009-23017 (2005).
157. Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol 9: 755-764 (2007).
158. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et
159. Blobel CP. Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol 12: 606-612 (2000).
160. Bacskai BJ, Xia MQ, Strickland K, Rebeck GW and Hyman BT. The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 97: 11551-11556 (2000).
161. Van Uden E, Mallory M, Veinbergs I, Alford M, Rockenstein E and Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci 22: 9298-9304 (2002).
162. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 280: 17777-17785 (2005).
163. Lleo A, Waldron E, von Arnim CA, Herl L, Tangredi MM, Peltan ID, et al. Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. J Biol Chem 280: 27303-27309 (2005).
164. Rosenberg PB. Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry 17: 503-514 (2005).
165. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713-48719 (2003).
166. Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC and Hashimoto Y. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci U S A 98: 13554-13559 (2001).
167. Kitazume S, Nakagawa K, Oka R, Tachida Y, Ogawa K, Luo Y, et al. In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. J Biol Chem 280: 8589-8595 (2005).
168. Garlind A, Brauner A, Hojeberg B, Basun H and Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 826: 112-116 (1999).
169. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C and Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 282: 11982-11995 (2007).
170. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT and Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164: 719-725 (2004).
171. Fukumoto H, Cheung BS, Hyman BT and Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389 (2002).
172. Tyler SJ, Dawbarn D, Wilcock GK and Allen SJ. alpha- and betasecretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299: 373-376 (2002).
173. Holsinger RM, McLean CA, Beyreuther K, Masters CL and Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783-786 (2002).
174. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3-4 (2003).
175. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101: 3632-3637 (2004).
176. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, et al. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci Res 54: 24-29 (2006).
177. Podlisny MB, Lee G and Selkoe DJ. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science 238: 669-671 (1987).
178. Sun X, Tong Y, Qing H, Chen CH and Song W. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. Faseb J 20: 1361-1368 (2006).
179. Fountoulakis M and Kossida S. Proteomics-driven progress in neurodegeneration research. Electrophoresis 27: 1556-1573 (2006).
180. Tamagno E, Bardini P, Guglielmotto M, Danni O and Tabaton M. The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic Biol Med 41: 202-212 (2006).
181. Mahley RW and Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537 (2000).
182. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA and Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817 (1997).
183. Nolan KA, Lino MM, Seligmann AW and Blass JP. Absence of vascular dementia in an autopsy series from a dementia clinic. J Am Geriatr Soc 46: 597-604 (1998).
184. Kalaria RN, Bhatti SU, Palatinsky EA, Pennington DH, Shelton ER, Chan HW, et al. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 4: 211-214 (1993).
185. Riekse RG, Leverenz JB, McCormick W, Bowen JD, Teri L, Nochlin D, et al. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. J Am Geriatr Soc 52: 1442-1448 (2004).
186. Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, et al. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 57: 98-103 (2005).
187. de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 28: 637-644 (2006).
188. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154 (1997).
189. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21: 153-160 (2000).
190. Guo Z, Qiu C, Viitanen M, Fastbom J, Winblad B, and Fratiglioni L. Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. J Alzheimers Dis 3: 585-591 (2001).
191. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 1: 61-77 (2002).
192. Johnson KA and Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging. 21: 289-292 (2000).
193. Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 41: 1155-1162 (2000).
194. Rodriguez G, Vitali P, Calvini P, Bordoni C, Girtler N, Taddei G, et al. Hippocampal perfusion in mild Alzheimer's disease. Psychiatry Res 100: 65-74 (2000).
195. de la Torre JC. Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol 57: 783-784 (2005).
196. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50: 1563-1571 (1998).
197. de la Torre JC. Critical threshold cerebral hypoperfusion causes Alzheimer's disease? Acta Neuropathol (Berl) 98: 1-8 (1999).
198. Meyer JS, Rauch G, Rauch RA and Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 21: 161-169 (2000).
199. Maalikjy Akkawi N, Borroni B, Agosti C, Magoni M, Broli M, Pezzini A, et al. Volume cerebral blood flow reduction in preclinical stage of Alzheimer disease: evidence from an ultrasonographic study. J Neurol 252: 559-563 (2005).
200. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman, A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57: 789-794 (2005).
201. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG and Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092-2097 (1997).
202. Williams TI, Lynn BC, Markesbery WR and Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27: 1094-1099 (2006).
203. Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T and Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94 (1994).
204. Sparks DL, Kuo YM, Roher A, Martin T and Lukas RJ. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 903: 335-344 (2000).
205. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856-5861 (2001).
206. Ghribi O, Larsen B, Schrag M and Herman MM. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 200: 460-467 (2006).
207. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10: 279-288 (2002).
208. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92: 628-636 (2005).
209. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 112: 455-469 (2005).
210. Velliquette RA, O'Connor T and Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25: 10874-10883 (2005).
211. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103: 18727-18732 (2006).
212. Xiong K, Cai H, Luo XG, Struble RG, Clough RW and Yan XX. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res 181: 435-446 (2007).
213. Yan XX, Xiong K, Luo XG, Struble RG and Clough RW. beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. J Comp Neurol 501: 52-69 (2007).
214. Jick H, Zornberg GL, Jick SS, Seshadri S and Drachman DA. Statins and the risk of dementia. Lancet 356: 1627-1631 (2000).
215. Wolozin B, Kellman W, Ruosseau P, Celesia GG and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443 (2000).
216. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331 (2000).
217. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, et al. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322: 893-898 (1997).
218. Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R and Forloni G. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J 348: 307-313 (2000).
219. Vance JE, Karten B and Hayashi H. Lipid dynamics in neurons. Biochem Soc Trans 34: 399-403 (2006).
220. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63: 1624-1628 (2004).
221. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62: 217-224 (2005).
222. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl 185: 71-77 (2006).
223. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62: 753-757 (2005).
224. Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H and Vassar R. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 280: 18755-18770 (2005).
225. Parsons RB, Price GC, Farrant JK, Subramaniam D, Adeagbo-Sheikh J and Austen BM. Statins inhibit the dimerization of betasecretase via both isoprenoid- and cholesterol-mediated mechanisms. Biochem J 399: 205-214 (2006).
226. Cole SL and Vassar R. Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol Dis 22: 209-222 (2006).
227. Parsons RB and Austen BM. Protein lipidation of BACE. Biochem Soc Trans 33: 1091-1093 (2005).
228. Ye S, Huang Y, Mullendorff K, Dong L, Giedt G, Meng EC, et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A 102: 18700-18705 (2005).
229. He X, Cooley K, Chung CH, Dashti N and Tang J. Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J Neurosci 27: 4052-4060 (2007).
230. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 282: 10873-10880 (2007).
231. Zhou W and Song W. Leaky scanning and reinitiation regulate BACE1 gene expression. Mol Cell Biol 26: 3353-3364 (2006).
232. Huang LE, Willmore WG, Gu J, Goldberg MA and Bunn HF. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 274: 9038-9044 (1999).
233. Sharp FR and Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 5: 437-448 (2004).
234. Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, et al. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm 111: 523-536 (2004).
235. Wen Y, Onyewuchi O, Yang S, Liu R and Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009: 1-8 (2004).
236. Harkany T, Abraham I, Konya C, Nyakas C, Zarandi M, Penke B, et al. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev Neurosci 11: 329-382 (2000).
237. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23: 10756-10764 (2003).
238. Huang LS, Sun G, Cobessi D, Wang AC, Shen JT, Tung EY, et al. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem 281: 5965-5972 (2006).
239. Zlokovic BV. Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. Adv Drug Deliv Rev 54: 1553-1559 (2002).
240. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60: 1707-1712 (2003).
241. Roberts GW, Gentleman SM, Lynch A and Graham DI. beta A4 amyloid protein deposition in brain after head trauma. Lancet 338: 1422-1423 (1991).
242. Graham DI, Gentleman SM, Lynch A and Roberts GW. Distribution of beta-amyloid protein in the brain following severe head injury. Neuropathol Appl Neurobiol 21: 27-34 (1995).
243. Cribbs DH, Poon WW, Rissman RA and Blurton-Jones M. Caspase-mediated degeneration in Alzheimer's disease. Am J Pathol 165: 353-355 (2004).
244. LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res 2: 389-402 (2005).
245. Kang JE, Cirrito JR, Dong H, Csernansky JG and Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A 104: 10673-10678 (2007).
246. Baram TZ and Hatalski CG. Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain. Trends Neurosci 21: 471-476 (1998).
247. Lindholm T, Cullheim S, Deckner M, Carlstedt T and Risling M. Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system. Exp Brain Res 142: 81-90 (2002).
248. Hyman BT, Strickland D and Rebeck GW. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch Neurol 57: 646-650 (2000).
249. Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 23: 4106-4115 (2004).
250. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci 25: 1219-1225 (2005).
251. Panegyres PK. The functions of the amyloid precursor protein gene. Rev Neurosci 12: 1-39 (2001).
252. http://www.athenagen.com/index.php?/athenagen/press_releases/45/.